Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
31.43 EUR | -0.91% | -0.44% | +0.29% |
Apr. 30 | Europeans down after inflation and Eurozone GDP. | AN |
Apr. 30 | Stock exchanges up at start; shower of macro in Europe | AN |
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- The company is in debt and has limited leeway for investment
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 35.09 times its estimated earnings per share for the ongoing year.
- The company's enterprise value to sales, at 3.43 times its current sales, is high.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The company is highly valued given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+0.29% | 7.67B | B+ | ||
-3.72% | 186B | C+ | ||
-2.60% | 107B | C | ||
-3.79% | 67.44B | A | ||
+2.66% | 50.03B | B- | ||
+16.39% | 47.81B | B- | ||
+4.00% | 41.03B | B+ | ||
+1.38% | 26.85B | B | ||
+1.52% | 25.82B | A- | ||
-1.17% | 25.01B | B |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- AMP Stock
- Ratings Amplifon S.p.A.